학술논문
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Document Type
Article
Author
Vano, Yann-Alexandre ; Elaidi, Réza; Bennamoun, Mostefa; Chevreau, Christine; Borchiellini, Delphine; Pannier, Diane; Maillet, Denis; Gross-Goupil, Marine; Tournigand, Christophe; Laguerre, Brigitte; Barthélémy, Philippe; Coquan, Elodie; Gravis, Gwenaëlle; Houede, Nadine; Cancel, Mathilde; Huillard, Olivier; Beuzeboc, Philippe; Fournier, Laure; Méjean, Arnaud; Cathelineau, Xavier; Doumerc, Nicolas; Paparel, Philippe; Bernhard, Jean-Christophe; de la Taille, Alexandre; Bensalah, Karim; Tricard, Thibault; Waeckel, Thibaut; Pignot, Géraldine; Braychenko, Elena; Caruso, Stefano; Sun, Cheng-Ming; Verkarre, Virginie; Lacroix, Guillaume; Moreira, Marco; Meylan, Maxime; Bougouïn, Antoine; Phan, Letuan; Thibault-Carpentier, Christelle; Zucman-Rossi, Jessica; Fridman, Wolf Herman; Sautès-Fridman, Catherine; Oudard, Stéphane
Source
In The Lancet Oncology May 2022 23(5):612-624
Subject
Language
ISSN
1470-2045